2 Pot Stocks to Buy Before Canada’s Cannabis 2.0 Legalization

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Hexo Corp (TSX:HEXO)(NYSE:HEXO) are headed for a collision course in the Cannabis 2.0 market. Now is the time to take sides.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canada will legalize cannabis-infused edibles for recreational use this month. The selection of products that will be available in retail outlets, however, will be limited. Nonetheless, the cannabis edibles, extracts, and topical market is estimated to be worth $2.7 billion annually.

Canopy Growth (TSX:WEED)(NYSE:CGC) and Hexo (TSX:HEXO)(NYSE:HEXO) are the pot stocks competing for market leadership in this growth opportunity and have delivered the significant gains to investors.

Potential champion

Canopy continues to disappoint investors so far, and the huge losses recently are worrisome. However, among all cannabis producers, this company has spent the most time and resources toward Cannabis 2.0. Its efforts will soon pay off.

The partnership with alcoholic beverage maker Constellation Brands is a clear sign that Canopy is likely to assume the leadership position in the cannabis-infused beverages market segment. Expect Canopy Growth to introduce multiple cannabis beverages, including zero and low-calorie drinks.

Mark Zekulin, Canopy’s interim CEO, believes that the cannabis beverages market will expand the cannabis consumer category to reach a larger portion of the population. Aside from beverages, Canopy will sell a variety of CBD products, including edibles and oils, later this fiscal year.

Since early July, Canopy has fallen sharply by 41%. But I expect the stock to gain strong momentum when the legal production and sales of cannabis beverages and edibles go into full swing. WEED could rise to $85 or a potential gain of 169%.

Worthy contender

Canopy isn’t the only cannabis producer with a solid financial backer. HEXO is likewise in the best position to be a big winner in the Cannabis 2.0 market. The main objective of forming Truss, a joint venture with beer maker Molson Coors Brewing, is to develop and market cannabis-infused beverages.

That market segment is Hexo’s primary focus. Last June, Hexo CEO Sebastien St.-Louis said that he hasn’t “seen anything else in the industry right now that compares to what we have today” with the first version of its cannabis-infused beverage.

But the company made it known that brisk sales won’t come from cannabis-infused beverages only. HEXO is also developing gummies and premium vape products. St.-Louis believes that these two could be the top-selling products that could match beverages in terms of market opportunity.

The competitive advantage of Hexo is its dominance in the province of Quebec. Currently, HEXO holds a leading market share of 30% in the province that ranks second to Ontario in terms of population size.

Hexo is down 19.0% since early June, but because of its enormous growth potential in the Cannabis 2.0 market, analysts are forecasting a 152% potential upside in the next 12 months.

Collision course

Expect a few kinks before the beverages and edibles markets get going. Health Canada is the process of crafting a strict legal framework that would ensure public safety. The cannabis sector is on the verge of creating valuable new growth opportunities with cannabis edibles and other alternative products.

But the winner in the Cannabis 2.0 market is a toss-up between team Canopy-Constellation and team Hexo-Molson Coors. It’s is going to be an exciting head-to-head battle. Pick your pot stock now, and may the better side win.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »